醫學美容已經不夠看了，全身換血才是下一波的回春治療。

美國一位史丹福大學的畢業生，就選擇這個標的作為他創業的開始。目前已經治療(服務)了一百五十名顧客，年齡大約在65到92歲，血液來源來自16到25歲的年輕人，預計會在美國五大城市布點，看來生意興隆。

為甚麼這個創業會通行無阻？主要是美國FDA法規也放鬆能正常輸血，『 #血液』預見會是未來的『新藥』。

 這項換血回春怎麼計價呢？這位史丹福大學畢業生標價一公升美金八千、以及兩公升美金一萬二千。(台幣24~36萬) 又會唸書，又有生意頭腦，不是嗎？

印象裡，日前，忘了日本哪個媒體報導，市川海老藏也去做這樣的美容(治療)，從底下的留言看來，在日本保守的社會應是群情譁然。

本來老態畢露，換血之後回春新生。我在猜這樣的客人應該會很快回到原點，依賴性應該很高。會處於換血上癮的狀態。

然後會讓人想到西方的吸血鬼故事不是憑空而來。(其實我們有必要回去看一下很多童話與傳說，有些東西不是空穴來風)

#血液是乘載人情感的液體，

#一滴血藏有你所有的訊息。

 輸血的整個醫學倫理與理論尚需重新檢討，更何況這種換血回春的新興行業(其實也是輸血)。從局部到全面，從病人到正常人。放大面積，放大規模。

很變態邪惡嗎？

等顧客人數越來越多，做的人口碑越來越廣，又看到診所門面高檔醫療，又有你喜歡的藝人代言，慢慢地戒心會卸除。而捐血(給這類回春中心)的年輕人，除了可賺外快以外，他的基因所有資料從此一覽無遺，也存在一個共同資料庫裏頭。

我們的食藥署都跟著美國FDA屁股走的，放行的時程應該也不遠了。

最後我引述一段話做個參考：

 「……….濺出的血液會餵養支配的力量，血祭深刻的模式存在數千年之久。現在顯現在醫療行為中，除非遇到緊急狀況，否則避免抽出我們的血，注入到他人身體裡。請注意九一一事件後，數周內抽出大量血液，即使沒有倖存者需要輸血。這些手法是宰制者的工具，與個人安泰無關。你不必為此自告奮勇。沒有人必須捐贈器官，因為器官移植對我們內部世界是種褻瀆，而牲畜的器官也不能移入人體，因為人類不是牲畜。這些議題令人非常難受，我們必須停止如此愚蠢的行為，畢竟醫療對我們的身體施暴時，次元也在遭受撕裂。那些醫療作法，總有一天會被認為是野蠻的。」

https://www.businessinsider.com/young-blood-transfusions-open-accepting-paypal-payments-cities-ambrosia-2019-1?fbclid=IwAR0h9ajmC-5ST8bs3lxXpikUyCGcLNqJ5IXvQt5D42rsCvrW4PSGqNCLH_s

A controversial startup that charges $8,000 to fill your veins with young blood now claims to be up and running in 5 cities across the US

A startup called Ambrosia that charges $8,000 to fill your veins with the blood of young people is now accepting PayPal payments for the procedure online.

Jesse Karmazin, a Stanford graduate who founded Ambrosia, told Business Insider this week that the company was up and running in five US cities.

Ambrosia recently completed its first clinical trial designed to assess the benefits of the procedure, but it has yet to publish the results. Karmazin previously told Business Insider the company wanted to open the first clinic in New York City, but that didnt happen.

To Jesse Karmazin, a startup founder and Stanford Medical School graduate, blood is the next big government-approved drug.

Roughly three years ago, Karmazin launched Ambrosia, a startup that fills the veins of older people with blood from younger donors, hoping the procedure would help conquer aging by rejuvenating the bodys organs. As Business Insider previously reported, theres little to no evidence to suggest this would work.

The company is now up and running, Karmazin told Business Insider on Wednesday. Ambrosia recently revamped its website with a list of clinic locations and is now accepting payments for the procedure via PayPal. Two options are listed: 1 liter of young blood for $8,000, or 2 liters for $12,000.

In the fall, Karmazin — who is not a licensed medical practitioner — told Business Insider he planned to open the first Ambrosia clinic in New York City by the end of the year. That didnt happen. Instead, he said, the sites where customers can get the procedure include Los Angeles; San Francisco; Tampa, Florida; Omaha, Nebraska; and Houston, Texas.

In 2017, Ambrosia enrolled people in a clinical trial designed to find out what happens when the veins of adults are filled with blood from younger people. While the results of that study have not been made public, Karmazin told Business Insider in September that they were "really positive."

Theres no scientific evidence to suggest that the treatments could help anyone, and several experts who spoke to Business Insider have raised red flags.

But because the Food and Drug Administration has approved blood transfusions, Ambrosias approach has been able to continue as an off-label treatment.

There appears to be significant interest. A week after putting up its first website in September, the company received roughly 100 inquiries about how to get the treatment, David Cavalier, Ambrosias chief operating officer at the time, told Business Insider in the fall. That led to the creation of a waiting list, Cavalier said.

In January, Cavalier told Business Insider hed left Ambrosia, leaving Karmazin as the companys only public employee.

Before departing from Ambrosia, Cavalier worked with Karmazin to scout several potential clinic locations in New York and organize talks with potential investors, he said.

Ambrosias first clinical trial

Because blood transfusions are already approved by federal regulators, Ambrosia does not need to demonstrate that its treatment carries significant benefits before offering it to customers.

As of September, the company had infused close to 150 people, ranging in age from 35 to 92, with the blood of younger donors, Cavalier said. Of those, 81 participated

in its clinical trial.

The trial, which involved giving patients 1.5 liters of plasma from a donor between the ages of 16 and 25 over two days, was conducted with David Wright, a physician who owns a private intravenous-therapy center in Monterey, California. Before and after the infusions, participants blood was tested for a handful of biomarkers, or measurable biological substances and processes thought to provide a snapshot of health and disease.

Trial participants paid $8,000, the same price as one of the procedures now listed on Ambrosias website.

"The trial was an investigational study," Cavalier said in September. "We saw some interesting things, and we do plan to publish that data. And we want to begin to open clinics where the treatment will be made available."

Karmazin added in September that he believed the trial showed the treatment to be safe.

Young blood and anti-aging: Are there any benefits?

Karmazin is right about the safety of blood transfusions and their capacity to save lives.

A simple blood transfusion, which involves hooking up an IV and pumping the plasma of a healthy person into the veins of someone whos undergone surgery or been in a car crash, for example, is one of the safest life-saving procedures available. Every year in the US, clinicians perform about 14.6 million of them, meaning about 40,000 blood transfusions happen on any given day.

But the science remains unclear about whether infusions of young blood can help fight aging.

In early experiments in mice, Tony Wyss-Coray, a director of the Alzheimers research center at Stanford University Medical School who founded a longevity startup focused on blood plasma called Alkahest, found that swapping old blood plasma for young blood plasma appeared to provide some limited cognitive benefits. The 150-year-old surgical technique he used, parabiosis — whose name comes from the Greek words "para," or "beside," and "bio," or "life" — involves exchanging the blood of two living organisms.

After Wyss-Corays mouse experiments, he and a team of Alkahest researchers took a big leap and in 2017 completed a monthlong study in which they transfused a standard unit of blood plasma from younger, healthy human volunteers into nine older adults with mild to moderate Alzheimers disease.

Their results were published this month in the journal JAMA Neurology. Because the study was small and short, the authors were fairly limited in drawing conclusions about what kind of benefits the plasma offered. They described the treatment as "safe, well tolerated, and feasible" and said the findings should be explored further in larger trials.

In a January interview with Business Insider, Alkahest CEO Karoly Nikolich described seeing cognitive boons in the older participants, including an improved sense of self and recognition of ones environment and location, as tested by a standard screening tool called the Mini-Mental State Examination.

But Alkahests work is very different from Ambrosias.

As Business Insider previously reported, Alkahest researchers want to develop drugs for age-related diseases that are inspired by their work with plasma; they are not looking to open a clinic.

The results looked really awesome

Nevertheless, Karmazin is optimistic that blood has a range of benefits. He got the idea for his company as a medical student at Stanford and an intern at the National Institute on Aging, where he watched dozens of traditional blood transfusions performed safely.

"Some patients got young blood, and others got older blood, and I was able to do some statistics on it, and the results looked really awesome," Karmazin told Business Insider in 2017. "And I thought this is the kind of therapy that Id want to be available to me."

So far, no one knows whether young blood transfusions can be reliably linked to lasting benefits.

Karmazin said that "many" of the roughly 150 people who had received the treatment described benefits including renewed focus, better memory and sleep, and improved appearance and muscle tone.

However, its tough to quantify these benefits before the studys findings are made public. Theres also the possibility that simply traveling to a lab in Monterey and paying to enroll in the study could have made the people feel better.

But Karmazin remains hopeful that the benefits he said hes seeing are the result of young-blood transfusions.

"Im really happy with the results were seeing," he said in September.